Drugs / LY2623091
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02300259 | Nov 2014 → Apr 2015 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02242981 | Sep → Nov 2014 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01237899 | Oct 2010 → Jan 2011 | chronic kidney disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02194465 | Aug 2014 → Mar 2015 | essential hypertension | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT01427972 | Sep 2011 → Mar 2013 | chronic kidney disease | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY2623091 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02300259 ↗ |
| Action | Inhibit | “Mineralocorticoid receptor antagonist” CHEMBL4088896 ↗ |
| Modality | Small molecule | — CHEMBL4088896 ↗ |
| Route | Oral | “Administered orally.” NCT01237899 ↗ |
| Target | NR3C2 | “Mineralocorticoid receptor antagonist” CHEMBL4088896 ↗ |